Expanding contraceptive options: A scoping review of medically approved contraceptive methods that are not in the WHO Medical Eligibility Criteria.

Sameera Mokkarala, Asantesana Kamuyango, James Kiarie, Nancy Kidula, Li Jiang, Sarita Sonalkar
{"title":"Expanding contraceptive options: A scoping review of medically approved contraceptive methods that are not in the WHO Medical Eligibility Criteria.","authors":"Sameera Mokkarala, Asantesana Kamuyango, James Kiarie, Nancy Kidula, Li Jiang, Sarita Sonalkar","doi":"10.1016/j.contraception.2025.110983","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The World Health Organization's (WHO) Medical Eligibility Criteria for contraceptive use (MEC) provides recommendations on the safety and efficacy of a range of contraceptive methods for users with various medical conditions. However, there are methods with medical regulatory agency approval that are not included in WHO guidance. Our objectives were to evaluate the evidence on methods that have regulatory approval for use in any member state, but which are not included in the MEC 2015, and to determine whether the evidence should be systematically reviewed to inform possible inclusion in a new WHO guideline.</p><p><strong>Study design: </strong>We conducted a scoping review of experimental studies found through two bibliographic databases (PubMed, Embase) from database inception to December 2023. Two reviewers screened abstracts and full texts to determine eligibility based on a priori inclusion and exclusion criteria; one additional reviewer resolved conflicts. Reviewers extracted data on method safety, efficacy, and acceptability using a standardized tool.</p><p><strong>Results: </strong>We identified three methods that met our review criteria: ormeloxifene, quinestrol-containing contraception, and mifepristone for emergency contraception (EC). Our initial search strategies yielded 386 total results. Five publications related to ormeloxifene, five to quinestrol-containing contraception, and 10 to mifepristone for EC were included. The data on these methods was highly variable.</p><p><strong>Conclusion: </strong>Rigorous systematic reviews of the evidence on safety, efficacy and dosage of ormeloxifene, quinestrol-containing contraception, and mifepristone for EC are needed to inform WHO recommendations on these methods. As these methods are already being used, international guidance for practitioners is essential.</p>","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110983"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contraception","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.contraception.2025.110983","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The World Health Organization's (WHO) Medical Eligibility Criteria for contraceptive use (MEC) provides recommendations on the safety and efficacy of a range of contraceptive methods for users with various medical conditions. However, there are methods with medical regulatory agency approval that are not included in WHO guidance. Our objectives were to evaluate the evidence on methods that have regulatory approval for use in any member state, but which are not included in the MEC 2015, and to determine whether the evidence should be systematically reviewed to inform possible inclusion in a new WHO guideline.

Study design: We conducted a scoping review of experimental studies found through two bibliographic databases (PubMed, Embase) from database inception to December 2023. Two reviewers screened abstracts and full texts to determine eligibility based on a priori inclusion and exclusion criteria; one additional reviewer resolved conflicts. Reviewers extracted data on method safety, efficacy, and acceptability using a standardized tool.

Results: We identified three methods that met our review criteria: ormeloxifene, quinestrol-containing contraception, and mifepristone for emergency contraception (EC). Our initial search strategies yielded 386 total results. Five publications related to ormeloxifene, five to quinestrol-containing contraception, and 10 to mifepristone for EC were included. The data on these methods was highly variable.

Conclusion: Rigorous systematic reviews of the evidence on safety, efficacy and dosage of ormeloxifene, quinestrol-containing contraception, and mifepristone for EC are needed to inform WHO recommendations on these methods. As these methods are already being used, international guidance for practitioners is essential.

扩大避孕选择:对未列入世卫组织医疗资格标准的经医学批准的避孕方法进行范围审查。
目标:世界卫生组织(世卫组织)的避孕药具使用医疗资格标准(MEC)就各种医疗状况的使用者使用一系列避孕方法的安全性和有效性提出了建议。然而,有些经医疗监管机构批准的方法未包括在世卫组织指南中。我们的目标是评估在任何成员国获得监管部门批准使用但未纳入2015年MEC的方法的证据,并确定是否应该对证据进行系统审查,以便为可能纳入新的世卫组织指南提供信息。研究设计:我们对从数据库建立到2023年12月通过两个书目数据库(PubMed, Embase)发现的实验研究进行了范围审查。两名审稿人筛选摘要和全文,根据先验的纳入和排除标准确定是否合格;另外一个审稿人解决了冲突。审稿人使用标准化工具提取方法安全性、有效性和可接受性的数据。结果:我们确定了三种符合我们审查标准的方法:奥美洛昔芬、含喹雌酮的避孕方法和米非司酮用于紧急避孕(EC)。我们最初的搜索策略总共产生了386个结果。包括5篇与奥美洛昔芬有关的出版物,5篇与含喹雌酮避孕有关的出版物,10篇与米非司酮用于EC有关的出版物。这些方法的数据变化很大。结论:需要对奥美洛昔芬、含喹雌酮的避孕药具和米非司酮用于EC的安全性、有效性和剂量的证据进行严格的系统审查,以便世卫组织就这些方法提出建议。由于这些方法已经在使用,因此对从业者的国际指导至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信